Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222514 | 0.86 | MTNR1A (0.57) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18239783 | 0.83 | HTR1D (0.62) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18239837 | 0.81 | MTNR1A (0.78) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18222541 | 0.81 | MTNR1A (0.54) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18222513 | 0.77 | MTNR1A (0.50) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18239879 | 0.76 | MTNR1A (0.50) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18239722 | 0.74 | MTNR1A (0.66) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18235623 | 0.72 | HTR1D (0.59) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL18239716 | 0.71 | MTNR1A (0.56) | MTNR1AMTNR1BPOLBALDH1A1 | |
| SCHEMBL18222551 | 0.71 | MTNR1A (0.68) | MTNR1AMTNR1BPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637451-B2 | Indole compound | ASTELLAS PHARMA INC. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3095781-A1 | INDOLE COMPOUND | Astellas Pharma Inc. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332966-A1 | INDOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332966-A1 | INDOLE COMPOUND | MTNR1A, MTNR1B, IDO2 | MTNR1A 1/4885MTNR1B 2/4885MAPT 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.